Dermata Therapeutics Q3 2026 net loss widens 67% to $2.82 million
DRMA•Dermata Therapeutics’ third-quarter 2026 net loss widened 67% year over year to $2.82 million. Net sales were $74,000, and cash, cash equivalents and restricted cash totaled $5.02 million at September 30.
1. Quarterly results
Dermata Therapeutics reported a third-quarter 2026 net loss of $2.82 million, up 67% year over year. Net sales reached $74,000 after the August 25 launch of Tome Foundational Treatment, its first commercial product. Selling, general and administrative expenses more than doubled to $2.76 million, primarily due to commercialization activities.
2. Cash and product plans
Cash, cash equivalents and restricted cash totaled $5.02 million at September 30, which the company said was sufficient to fund operations into the first quarter of 2027. Tome Clearing Treatment entered clinical evaluation in October, with a commercial launch expected in the first half of 2027.
